|1.||Varani, James: 4 articles (08/2015 - 11/2003)|
|2.||Dame, Michael K: 2 articles (08/2015 - 10/2009)|
|3.||Zhang, Jian: 2 articles (11/2004 - 11/2003)|
|4.||McClintock, Shannon: 1 article (08/2015)|
|5.||Ouillette, Peter D: 1 article (08/2015)|
|6.||Allen, Ronald: 1 article (08/2015)|
|7.||Khan, Shazli P: 1 article (08/2015)|
|8.||Perone, Patricia: 1 article (08/2015)|
|9.||Aslam, Muhammad N: 1 article (08/2015)|
|10.||Kunkel, Steven L: 1 article (08/2015)|
|1.||Breast Neoplasms (Breast Cancer)
11/01/2004 - "This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARalpha, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy."
11/01/2004 - "MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. "
|3.||Myeloid Leukemia (Leukemia, Myelocytic)
08/01/2015 - "MDI 301, a retinoic acid receptor-α - agonist, suppressed the growth of several human myeloid leukemia cell lines (HL60, NB4, OCI-M2, and K562) in vitro and induced cell-substrate adhesion in conjunction with upregulation of CD11b. "
08/01/2015 - "MDI 301 suppresses myeloid leukemia cell growth in vitro and in vivo without the toxicity associated with all-trans retinoic acid therapy."
11/01/2003 - "The ability of the synthetic retinoid MDI-301, in which the carboxylic acid of 9- cis-retinoic acid (9-cis-RA) is replaced with an ester linkage, to induce epidermal and dermal thickening and skin irritation (erythema and flaking) in hairless (rhino) mice following its topical application was investigated in comparison with that of 14-all- trans-retinoic acid (14-all-trans-RA) and 9-cis-RA. "
|3.||retinoic acid receptor alpha
|4.||Tretinoin (Retinoic Acid)
|5.||Retinoic Acid Receptors (Retinoic Acid Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)